Clinical trials: High-risk PCI
Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
Imaging Markers of High-Risk Plaque Phenotype for Predicting Post-PCI Outcomes
Despite the widespread use of stents, previous studies have shown that stent implantation mainly relieves symptoms but may not significantly improve long-term outcomes in patients with stable coronary artery disease.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention (PCI), Atherosclerosis of Coronary Artery
- Trial name
- IMPACT-PCI (NCT07117084)
- Testing
- CCTA-derived Plaque Quantification
- Where
- 3 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Cardiogenic Shock, PCI Patients
Clinical Outcomes of Contemporary IMPELLA Devices in Cardiogenic Shock and High-risk Percutaneous Coronary Intervention
The IMMERGE registry is an observational, international multicentric study, including patients underwent IMPELLA implantation in the participating centers both for cardiogenic shock and high-risk PCI.
- Conditions
- Cardiogenic Shock, PCI Patients, Mechanical Circulatory Support
- Trial name
- IMMERGE (NCT06690567)
- Testing
- Impella implantation
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Induced Acute Kidney Injury, High-risk Percutaneous Coronary Intervention
Protect Kidney Trial
This trial is a randomized, controlled, open-label, parallel study. Patients at high risk for contrast induced acute kidney injury (CI AKI) and planned high-risk percutaneous coronary intervention (PCI) will be randomized to…
- Trial name
- NCT04321148
- Testing
- standard of care PCI, Impella-protected PCI
- Where
- Germany
- Volunteers
- 224 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Chronic Obstructive Pulmonary Disease, Alpha 1-Antitrypsin Deficiency
Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients
Pulmonary rehabilitation (PR) including exercise training is highly effective by improving health-related quality of life, exercise capacity and symptoms in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03802357
- Testing
- Exercise training
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Schön Klinik Berchtesgadener Land
IHD, LV Dysfunction
Coronary Artery Bypass Grafts or Percutaneous Coronary Intervention for High Risk Patients
Most patients with Left Ventricular Systolic Dysfunction (LVSD) or heart failure (HF) have coronary artery disease (CAD) while some patients also have renal disease.
- Trial name
- NCT05534698
- Testing
- PCI, CABG
- Where
- Denmark
- Volunteers
- 1,550 people
- Sponsor
- Danish Study Group
Acute Coronary Syndrome
Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI
The goal of acute coronary syndrome (ACS) therapy is to successfully restore both epicardial blood flow and myocardial perfusion.
- Trial name
- NCT02201667
- Testing
- Ticagrelor, clopidogrel, Aspirin
- Where
- China
- Volunteers
- 444 people
- Sponsor
- RenJi Hospital
Acute Coronary Syndrome, Contrast-Induced Acute Kidney Injury
Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome
This observational study aims to identify predictors of contrast-induced acute kidney injury (CI-AKI) in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
- Trial name
- PC-AKI-ACS (NCT07294911)
- Testing
- Observational data collection
- Where
- Kazakhstan
- Volunteers
- 88 people
- Sponsor
- Karaganda Medical University
Coronary Artery Disease, Chronic Stable Angina
LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients
This study aims to demonstrate that the BioFreedom™ Ultra Drug Coated Stent (DCS) is non-inferior to the BioFreedom™ DCS, with respect to in-stent late lumen loss, and that it has safety characteristics similar to the BioFreedom™…
- Conditions
- Coronary Artery Disease, Chronic Stable Angina, Unstable Angina, Silent Ischemia
- Trial name
- NCT06657326
- Testing
- BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent, BioFreedom™ stainless steel Biolimus A9™-coated stent
- Where
- 6 sites in Malaysia
- Volunteers
- 444 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease
The Prospective, Multicenter, Randomized Controlled Trial of the VentriCure Interventional Left Ventricular Assist System
This study aims to evaluate the safety and effectiveness of the VentriCure interventional left ventricular assist system for short-term ventricular support during high-risk percutaneous coronary intervention (HRPCI) in…
- Trial name
- NCT07675005
- Testing
- VentriCure Interventional left ventricular assist system, ECMO
- Volunteers
- 220 people
- Sponsor
- Life Shield Medical Technology Co., LTD
Coronary Artery Disease
The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance
Continuing high dose clopidogrel treatment after elective PCI decreased adverse cardiac events in patients with clopidogrel resistance
- Trial name
- EFFICIENT (NCT01032668)
- Testing
- Clopidogrel
- Where
- Turkey (Türkiye)
- Volunteers
- 192 people
- Sponsor
- Bursa Postgraduate Hospital
Long-term Major Cardiovascular Events, Myocardial Infarction
CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction
The purpose of this registry is to evaluate long-term clinical events in patients with acute myocardial infarction who were treated with percutaneous coronary intervention.
- Conditions
- Long-term Major Cardiovascular Events, Myocardial Infarction, Percutaneous Coronary Intervention
- Trial name
- COREA-AMI (NCT02385682)
- Testing
- Percutaneous coronary intervention
- Volunteers
- 4,748 people
- Sponsor
- Kiyuk Chang
Percutaneous Coronary Intervention, Multivessel Coronary Artery Disease
Residual Inflammatory Risk-Guided colcHicine in Elderly Trial
The goal of this clinical trial is to compare low-dose colchicine (0.5 mg Once Daily) with no specific intervention in selected elderly patients (60-80 years old) with residual inflammatory risk (hs-CRP≥ 2mg/L) and multivessel…
- Conditions
- Percutaneous Coronary Intervention, Multivessel Coronary Artery Disease, Elderly Patients, C-Reactive Protein
- Trial name
- RIGHT (NCT06025071)
- Testing
- colchicine
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Atherosclerotic Plaque
Efficacy and Safety of Intravascular High-pressure Cutting Balloon Catheters for PCI
The purpose of this study was to evaluate the safety and efficacy of intravascular high-pressure cut balloon catheter compared to cut balloon catheter during PCI, and to support product registration and clinical application.
- Trial name
- NCT06214754
- Testing
- PCI
- Where
- 12 sites in China
- Volunteers
- 168 people
- Sponsor
- BrosMed Medical Co., Ltd
Coronary Microvascular Dysfunction
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
In this study, investigators enrolled patients with coronary heart disease who were scheduled to undergo percutaneous coronary intervention (PCI) and had high-risk plaques according to computed tomography angiography (CTA).
- Trial name
- PCI (NCT05984537)
- Testing
- Bivalirudin, standard heparin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
Chronic Coronary Syndrome, Acute Coronary Syndromes
Optimal LDL-C Target in High-risk Patients After PCI
Extensive evidence from epidemiological, genetic, and randomized controlled trials (RCTs) of lipid-lowering therapies has firmly established a causal relationship between low-density lipoprotein cholesterol (LDL-C) and…
- Conditions
- Chronic Coronary Syndrome, Acute Coronary Syndromes, Percutaneous Coronary Intervention, High Risk Patient
- Trial name
- REC-SAFETARGET (NCT06821711)
- Testing
- Intensive LDL-C control, Conventional LDL-C control
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- Xijing Hospital
Coronary Artery Lesion
ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis
The primary objectives of this trial are: In patients at high-risk for restenosis, To assess non-inferiority of the everolimus-eluting bioresorbable scaffold (BRS) to the everolimus eluting cobalt chromium metallic stent (EES) in…
- Trial name
- Compare Absorb (NCT02486068)
- Testing
- ABSORB scaffold, Xience
- Where
- 44 sites in Belgium, Czechia and 7 more
- Volunteers
- 1,670 people
- Sponsor
- European Cardiovascular Research Center
Coronary Artery Disease
Routine Angiography Follow-Up After Percutaneous Coronary Intervention in High-Risk Patients
Comparison of clinical outcomes between routine angiography follow-up and routine clinical follow-up after percutaneous coronary intervention in high-risk patients.
- Trial name
- NCT05923489
- Testing
- Routine Angiography Follow-up, Routine Clinical Follow-up
- Where
- China
- Volunteers
- 2,618 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Coronary Artery Disease, Acute Coronary Syndrome
Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT
Objective: To evaluate the safety of bioresorbable polymer-coated everolimus-eluting Synergy® stent followed by 1-month dual antiplatelet therapy in patients at high-bleeding risk.
- Trial name
- POEM (NCT03112707)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- Italy
- Volunteers
- 1,023 people
- Sponsor
- Humanitas Hospital, Italy
Acute Coronary Syndrome
Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity
MAIN AIM: To compare the pharmacological potency of administering adjusted 600 mg clopidogrel loading doses and 60 mg prasugrel in patients with high on-clopidogrel platelet reactivity (HPR) after PCI.
- Trial name
- TREAT-HPR (NCT01493999)
- Testing
- Clopidogrel reloading, Prasugrel
- Where
- Hungary
- Volunteers
- 147 people
- Sponsor
- University of Pecs
Coronary Stenoses
TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI
This study evaluates the efficacy and safety of tailored antithrombotic therapy with early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month…
- Trial name
- TAILORED-CHIP (NCT03465644)
- Testing
- Tailored antithrombotic strategy, Conventional antithrombotic strategy
- Where
- 22 sites in South Korea
- Volunteers
- 2,018 people
- Sponsor
- Duk-Woo Park, MD